Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Wolfgangrene's charts -- Ignore unavailable to you. Want to Upgrade?

To: The Ox who wrote (1534)	9/14/2015 10:39:37 AM
From: Biotech Jim	1 Recommendation Recommended By The Ox Read Replies (1) \| Respond to of 3976

Thanks Ox- I reloaded some of my RIGL common at just under $3, and am looking to unload them in the mid term. RIGL has had some good news recently, and has two Ph3 tials ongoing for ITP, Idiopathic Thrombocytopenia Purpura (low platelets). Here are the PRs for the recent news items. Rigel and Aclaris Therapeutics International Sign License Agreement for JAK Inhibitors to Treat Skin Disorders ir.rigel.com Rigel Granted Orphan Drug Designation for Fostamatinib in ITP ir.rigel.com